T. Rowe Price Investment Management, Inc. Denali Therapeutics Inc. Transaction History
T. Rowe Price Investment Management, Inc.
- $158 Billion
- Q2 2025
A detailed history of T. Rowe Price Investment Management, Inc. transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, T. Rowe Price Investment Management, Inc. holds 3,246,934 shares of DNLI stock, worth $42.9 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
3,246,934Holding current value
$42.9 Million% of portfolio
0.03%Shares
5 transactions
Others Institutions Holding DNLI
# of Institutions
244Shares Held
134MCall Options Held
148KPut Options Held
15.4K-
Black Rock Inc. New York, NY13.2MShares$174 Million0.01% of portfolio
-
Baillie Gifford & CO12MShares$158 Million0.13% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.8MShares$156 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD6.58MShares$87 Million0.01% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL6.26MShares$82.8 Million0.02% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $1.77B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...